Coeptis Therapeutics Inc Financials
This page shows Coeptis Therapeutics Inc (COEP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Coeptis Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Coeptis Therapeutics Inc generates $0.61 in operating cash flow (-$6.6M OCF vs -$10.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Coeptis Therapeutics Inc earns $-25.4 in operating income for every $1 of interest expense (-$10.1M vs $396K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Coeptis Therapeutics Inc generated $0 in revenue in fiscal year 2024.
Coeptis Therapeutics Inc's EBITDA was -$9.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.8% from the prior year.
Coeptis Therapeutics Inc reported -$10.9M in net income in fiscal year 2024. This represents an increase of 48.9% from the prior year.
Coeptis Therapeutics Inc earned $-5.65 per diluted share (EPS) in fiscal year 2024. This represents an increase of 65.9% from the prior year.
Coeptis Therapeutics Inc held $533K in cash against $150K in long-term debt as of fiscal year 2024.
Coeptis Therapeutics Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 19.8% from the prior year.
Coeptis Therapeutics Inc invested $2.3M in research and development in fiscal year 2024. This represents a decrease of 65.0% from the prior year.
COEP Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $237K+18.3% | $201K+219.2% | $63K | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $45K0.0% | $45K0.0% | $45K | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $192K+23.6% | $156K+777.8% | $18K | $0 | $0 | $0 | $0 | $0 |
| R&D Expenses | $587K+102.3% | $290K+235.0% | $87K-74.8% | $344K-57.6% | $812K+103.5% | $399K-48.7% | $777K-23.3% | $1.0M |
| SG&A Expenses | $201K-61.8% | $527K+95.9% | $269K-25.5% | $361K+108.6% | $173K-27.6% | $239K+38.5% | $173K-20.2% | $216K |
| Operating Income | -$2.5M+45.2% | -$4.5M-11.4% | -$4.1M-87.6% | -$2.2M-1.0% | -$2.1M+24.3% | -$2.8M+3.2% | -$2.9M+13.2% | -$3.4M |
| Interest Expense | $63K-7.6% | $68K-5.2% | $71K-9.1% | $79K+54.4% | $51K-22.9% | $66K-67.1% | $201K+1349.6% | $14K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2.9M+33.1% | -$4.3M-26.7% | -$3.4M-13.6% | -$3.0M-64.7% | -$1.8M+39.7% | -$3.0M-1.1% | -$3.0M+20.1% | -$3.8M |
| EPS (Diluted) | $-0.58 | $-1.17-5.4% | $-1.11+79.6% | $-5.44 | $-0.05+37.5% | $-0.080.0% | $-0.08 | $-15.77 |
COEP Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.2M+16.3% | $12.2M-9.4% | $13.5M+51.0% | $8.9M-0.5% | $9.0M+113.3% | $4.2M+7.8% | $3.9M-14.8% | $4.6M |
| Current Assets | $6.0M+62.1% | $3.7M-20.6% | $4.7M+342.4% | $1.1M-23.0% | $1.4M-31.5% | $2.0M+44.3% | $1.4M-21.1% | $1.7M |
| Cash & Equivalents | $4.9M+145.8% | $2.0M-53.2% | $4.3M+701.0% | $533K-53.2% | $1.1M-26.9% | $1.6M+51.1% | $1.0M-29.9% | $1.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $83K+175.0% | $30K | N/A | $0 | N/A | N/A | N/A | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.3M-36.1% | $5.1M-14.7% | $6.0M+18.8% | $5.0M+26.9% | $4.0M-11.9% | $4.5M-10.5% | $5.0M+34.0% | $3.8M |
| Current Liabilities | $2.7M-39.5% | $4.5M-20.8% | $5.7M+25.2% | $4.5M+31.2% | $3.4M-5.1% | $3.6M-15.7% | $4.3M+43.9% | $3.0M |
| Long-Term Debt | $150K0.0% | $150K | N/A | $150K0.0% | $150K0.0% | $150K0.0% | $150K0.0% | $150K |
| Total Equity | $10.4M+70.0% | $6.1M-5.9% | $6.5M+91.6% | $3.4M-29.9% | $4.8M+1190.2% | -$443K+61.2% | -$1.1M-240.1% | $814K |
| Retained Earnings | -$108.4M-2.3% | -$106.0M-4.3% | -$101.7M-3.7% | -$98.0M-3.0% | -$95.2M-2.0% | -$93.4M-3.4% | -$90.4M-3.4% | -$87.4M |
COEP Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.2M+10.2% | -$2.4M-1.3% | -$2.4M-64.7% | -$1.4M+24.1% | -$1.9M-33.5% | -$1.4M+25.5% | -$1.9M-12.3% | -$1.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0-100.0% | $100K | $0 | $0+100.0% | -$100K | $0 |
| Financing Cash Flow | $5.1M+3947.9% | $125K-97.9% | $6.1M+733.6% | $732K-50.4% | $1.5M-24.1% | $1.9M+24.4% | $1.6M-10.8% | $1.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
COEP Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.0%+3.5pp | 77.5%+49.3pp | 28.2% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1043.2%+1209.7pp | -2252.9%+4199.6pp | -6452.6% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -1220.8%+939.1pp | -2159.9%+3281.0pp | -5440.9% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | 0.0% | N/A | N/A | N/A |
| Return on Assets | -20.4%+15.1pp | -35.5%-10.1pp | -25.4%+8.4pp | -33.8%-13.4pp | -20.4%+51.9pp | -72.3%+4.8pp | -77.1%+5.1pp | -82.2% |
| Current Ratio | 2.21+1.4 | 0.830.0 | 0.82+0.6 | 0.23-0.2 | 0.40-0.2 | 0.55+0.2 | 0.32-0.3 | 0.59 |
| Debt-to-Equity | 0.01-0.0 | 0.02-0.9 | 0.92+0.9 | 0.04+0.0 | 0.03+0.4 | -0.34-0.2 | -0.13-0.3 | 0.18 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.23), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Coeptis Therapeutics Inc's annual revenue?
Coeptis Therapeutics Inc (COEP) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Coeptis Therapeutics Inc profitable?
No, Coeptis Therapeutics Inc (COEP) reported a net income of -$10.9M in fiscal year 2024.
What is Coeptis Therapeutics Inc's earnings per share (EPS)?
Coeptis Therapeutics Inc (COEP) reported diluted earnings per share of $-5.65 for fiscal year 2024. This represents a 65.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Coeptis Therapeutics Inc's EBITDA?
Coeptis Therapeutics Inc (COEP) had EBITDA of -$9.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Coeptis Therapeutics Inc have?
As of fiscal year 2024, Coeptis Therapeutics Inc (COEP) had $533K in cash and equivalents against $150K in long-term debt.
What is Coeptis Therapeutics Inc's operating cash flow?
Coeptis Therapeutics Inc (COEP) generated -$6.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Coeptis Therapeutics Inc's total assets?
Coeptis Therapeutics Inc (COEP) had $8.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Coeptis Therapeutics Inc spend on research and development?
Coeptis Therapeutics Inc (COEP) invested $2.3M in research and development during fiscal year 2024.
How many shares does Coeptis Therapeutics Inc have outstanding?
Coeptis Therapeutics Inc (COEP) had 2M shares outstanding as of fiscal year 2024.
What is Coeptis Therapeutics Inc's current ratio?
Coeptis Therapeutics Inc (COEP) had a current ratio of 0.23 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Coeptis Therapeutics Inc's debt-to-equity ratio?
Coeptis Therapeutics Inc (COEP) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Coeptis Therapeutics Inc's return on assets (ROA)?
Coeptis Therapeutics Inc (COEP) had a return on assets of -122.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Coeptis Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Coeptis Therapeutics Inc (COEP) had $533K in cash against an annual operating cash burn of $6.6M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Coeptis Therapeutics Inc's Piotroski F-Score?
Coeptis Therapeutics Inc (COEP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Coeptis Therapeutics Inc's earnings high quality?
Coeptis Therapeutics Inc (COEP) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Coeptis Therapeutics Inc cover its interest payments?
Coeptis Therapeutics Inc (COEP) has an interest coverage ratio of -25.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.